Docket No. MCP-5016 NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Wynn et al.

Serial No. : 10/608,681

Art Unit:

Filed

: June 27, 2003

Examiner:

For

: SOFT TABLET CONTAINING HIGH MOLECULAR WEIGHT

CELLULOSICS

I hereby certify that this correspondence is being deposited with the United States Postal Service se first class mail in an envelope addressed to: Commissioner For Patents, P. D. Sox 1650. Alexandria, VA 2233-1455 on

Michele G. Mengini
ne of applicant, assignee, or Registered Representative

Costs of Companyo

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☑ In accordance with §1.	.97(b), since this Information
Disclosure Statement is being fi	led either within three months
of the filing date of the above-	identified national application
(other than a continued prosecut	ion application under
§1.53(d)), within three months o	of the date of entry into the
national stage of the above iden	tified application as set forth
in §1.491, or before the mailing	date of a first Office Action
on the merits of the above-ident	ified application, or before
the mailing date of a first Offi	ce Action after the filing of a
request for continued examination	on under §1.114, no additional
fee is required.	
_	.129(a), this Information
Disclosure Statement is being fi	_
first or □second After Final Su	bmission, therefore:
Statement in Acco	ordance with §1.97(e)
(attached); or	
Please charge Dep	posit Account No. 10-
0750/ / th	he fee of \$180.00 as set forth
in §1.17(p).	
☐ In accordance with §1.	.97(c), this Information
Disclosure Statement is being fi	
in §1.97(b) above but before the	=
Action under §1.113 or a Notice	
an action that otherwise closes	
accompanied by one of:	-
	ordance with §1.97(e)
(attached); or	
,	

Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in \$1.17(p).
57
Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
•
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
•
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
enclosed because this U.S. patent application was filed after
June 30, 2003 or this international application has entered the

waiver of requirement under 37 CFR 1.98 (a)(2)(i).
$\hfill \Box$ There are no listed references which are not in the English language.
☑ The relevance of those listed references which are not in the English language can be found in an attached English-language Abstract, English-language equivalent, or complete English language translation.
Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

national stage under 35 USC §371 after June 30, 2003 (see USPTO

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D: U.S. Serial No. 10/607,766 filed June 27, 2003 (Atty. Docket No. MCP-5014 NP)

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/MCP5016NP/MGM. This form is submitted in triplicate.

Respectfully submitted,

Michele (Mangini Reg. No. 35,806 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2810 DATED: September 24, 2003



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 9651-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 2

Application Number 10/608,681 Filing Date June 27, 2003 David Wynn et al First Named Inventor Group Art Unit Examiner Name Attorney Docket Number MCP-5016 NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
/C D-/ -		USP 23, (1995) <1218> p. 1981	
/G.B./		USP 24, 2000 Version, 19-20 and 856-857 (1999)	_
C.B./		LIEBERMAN, ET Al., Pharmaceutical Dosage Forms, Volume 3, pp.138-150 (1990)	
0.0.	_	LACHMAN ET AL., The Theory and Practice of Industrial Pharmacy, Chapter 11, pp. 293-345 (3 Ed. 1986)	
/C.B./		LIEBERMAN ET AL., Pharmaceutical Dosage Forms - Tablets, Volume 2, 2 rd ed., Marcel Dekker Inc., 1990, pp. 213-217, 327-329	
	_		
	_		
	-		_
	-		_
	-		
			_
	_		

Examiner	/Courtney Brown/	Date	07/15/2008
Signature	/Courtney Brown/	Considered	01/13/2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Nor Statement: This form is estimated to take 2.0 hours, to complete. Then will vary dispending upon the needs of the individual case. Any promments on the mismont of time you are required to complete this form about be sent to the Cheel information Officer. U. S. Patent and Trademan Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTC/S8/084 (06-00)
Approved for use through 10/31/2002, OMB 6631-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a coffection of information unless it displays a valid OMB control number.

and a cafection of information uses at displays a water URB covers number.

Application Number 10600,881

Filling Date June 27, 2003

First Named Inventor David Wynn et al.

Group Art Unit

Examiner Name

Attorney Docket Number MCP-5016 NP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

U.S. PATENT DOCUMENTS

U.S. Patent Document		ument				
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
/C.B./		4,818,539		Shaw et al.	4-04-1989	
		4,851,226		Julian et al.	7-25-1989	
		4,882,154		Yang et al.	11-21-1989	
	1	4,906,478		Valentine et al.	3-06-1990	
		5,075,114		Roche	12-24-1991	
		5,275,822		Valentine et al.	1-04-1994	
		5,336,486		Acharya	8-09-1994	
		5,489,436		Hoy et al.	2-06-1996	
\perp		6,103,260		Luber et al	8-15-2000	
		6,432,442		Bushler et al.	8-13-2002	
1		6,471,991		Robinson et al.	10-29-2002	
V		5,989,534		Samain	11-23-1999	

FORFIGN PATENT DOCUMENTS

		Foreign	Petent Docume	int	Name of Patentee or	Date of Publication Pages, Columns, Lines of Cited Document where relevant		
Examiner Initials	Cite No.1	Office ³	Number ⁴ K	indCode ⁵	Applicent of Cited Document	mm-dd-yyyy	passeges or relevent figures appear	70
/C.B./		wo	88/06893	A1	Benzon Pharma A/S	Sept. 22, 1988		
/C.B./		wo	00/30617	A1	Cima Labs Inc.	June 2, 2000		
/C.B./		Đ.	5306229		Lederle Japan Ltd. (with complete English Translation)	Nov. 19, 1993		
/C.B./		JP	P200-95710	Α .	Taisho Seiyaku K.K. (English Translation Only)	April 4, 1990		
/C.B	/	wo	95/02391	A1	L'Oreal (See English-Language equivalent U.S. 5,989,534)	Jan. 26, 1995		


Signature	/Oddriney Diowii/	Considered	07/15/2006
'EXAMINER:	Initial if reference considered, whether or not citation is in con	formance with MPEP 609, Draw line	through citation if not in conformance
and not consi	idered. Include copy of this form with next communication to a	policant.	

I Unique craftion designation number. Size attached Kinds of U.S. Pattert Documents. Scritter Office that issued the document by the how-letter code (VIVID Standard ST 3). For Japanese patent document, by indiscions on the year of the repring not the Emperor must proceed the serial number of the pattent document. s Kind of document by the appropriate symbols as indicated on the document under WIPID Stendard ST. 16 if possible. A Proceedings in the Standard is to state a check must here it is formation and the standard s

(Countries Drawn)

Burdon Nov Statement: This form is estimated to take 20 hours to complete. Then will vary despending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Cificer, U. S. Patent and Trademark. Office, Washington, D.C. 2023.

Office, Washington, D.C. 2023.



Application Number 10/608,681 Filing Date First Named Inventor June 27, 2003 David Wynn et al. Group Art Unit Examiner Name Attorney Docket Number MCP-5016 NP

U.S. PATENT DOCUMENTS
U.S. Patent Document Name of Patentee or Applicant Pages, Columns, Lines, Examiner Initials Cite where relevant passages or relevant figures appear of Cited Document No.1 Number (if known)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign Pa	Number ⁴	ent KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	Τ [¢]
	ļ						
		}		}	+		
					+		
	1				1		
		OTHER PRIOR ART - N					
Examiner 's Initials*	Cite No.1	Include name of the author (in C title of the item (book, magazine volume-issue number(s	, journal, se	erial, sympo	osium, catalo	g, etc.), date, page(s),	T ²
_/C.B./	_	Application of U.S. Serial No. 10/607,76	66 filed June	27, 2003 (At	ty Docket MCF	-5014 NP)	
	=						
	=						
	-						
	-						

Examiner Signature	/Courtney Brown/	Date Considered	07/15/2008